Australia's most trusted
source of pharma news
Tuesday, 22 October 2024
Posted 21 October 2024 PM
PharmAust has rebranded to Neurizon Therapeutics as it pivots its focus solely on neurodegenerative diseases.
Over the past year, the company has deprioritised programs in animal health and oncology to devote resources to its lead drug monepantel, now known as NUZ-001, for the treatment of neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.